Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ArtemiCoffee in Biochemical Recurrence of Prostate Cancer
NCT05478239Phase 2Completed
- Start
- Aug 2023
- Primary completion
- Jul 2026
- Modality
- Dietary Supplement
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ArtemiCoffee in prostate cancer (PCa). Primary endpoint: Proportion of patients who achieve a 50% decline in PSA levels at 24 weeks. Started Aug 2023; status: completed.
02
Drugs
ArtemiCoffee
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05478239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478239.